AdaptHealth (NASDAQ:AHCO – Get Free Report) is projected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect AdaptHealth to post earnings of ($0.0505) per share and revenue of $725.87 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.
AdaptHealth (NASDAQ:AHCO – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($1.16). AdaptHealth had a negative net margin of 7.07% and a positive return on equity of 3.36%. The company had revenue of $740.31 million during the quarter, compared to analysts’ expectations of $846.77 million. During the same quarter in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was down 7.5% compared to the same quarter last year.
AdaptHealth Trading Down 1.5%
NASDAQ AHCO opened at $5.93 on Tuesday. The company has a quick ratio of 0.98, a current ratio of 1.12 and a debt-to-equity ratio of 1.37. The firm has a 50 day moving average of $5.86 and a two-hundred day moving average of $9.28. The stock has a market capitalization of $808.52 million, a PE ratio of -3.47 and a beta of 1.42. AdaptHealth has a 52 week low of $5.21 and a 52 week high of $13.43.
Insider Buying and Selling at AdaptHealth
In related news, Director Kenneth Samet acquired 23,500 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $149,930.00. Following the transaction, the director directly owned 48,569 shares of the company’s stock, valued at approximately $309,870.22. This trade represents a 93.74% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.95% of the stock is currently owned by company insiders.
Analyst Ratings Changes
AHCO has been the topic of a number of recent analyst reports. Truist Financial dropped their price objective on AdaptHealth from $14.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, August 5th. Royal Bank Of Canada cut their price target on AdaptHealth from $15.00 to $8.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Robert W. Baird decreased their target price on shares of AdaptHealth from $10.00 to $9.00 and set an “outperform” rating for the company in a research note on Thursday, September 17th. Canaccord Genuity Group set a $10.00 price objective on shares of AdaptHealth in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group raised AdaptHealth from a “hold” rating to a “buy” rating and increased their target price for the stock from $11.00 to $13.00 in a research note on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.14.
Get Our Latest Stock Analysis on AHCO
About AdaptHealth
AdaptHealth Corp. (NASDAQ: AHCO) is a provider of home medical equipment, supplies and related healthcare services in the United States. The company helps patients manage chronic conditions and recover from illness or injury outside of traditional healthcare facilities, working with individuals, caregivers, physicians and payers.
Its products and services include respiratory equipment and supplies, oxygen therapy, sleep therapy devices such as continuous positive airway pressure systems, diabetes management products, mobility and accessibility equipment, and other durable medical equipment.
Read More
- Five stocks we like better than AdaptHealth
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for AdaptHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AdaptHealth and related companies with MarketBeat.com's FREE daily email newsletter.
